Your session is about to expire
← Back to Search
Nivolumab + Ipilimumab for Rare Cancers
Study Summary
This trial is studying nivolumab and ipilimumab in treating patients with rare tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been cancer-free from another type for at least one year.I have a rare cancer type and can provide samples, except if I have GTD.My cancer has PD-L1 amplification, confirmed by a study chair.I was in the NCI-MATCH trial but didn't match any treatments or have finished all recommended treatments.My cancer has worsened after treatment and no other standard treatments are suitable or available for me.My cancer's origin is unknown.I've had a CT scan or MRI within the last 28 days showing measurable disease.My condition worsened after treatment, or no effective treatment exists for me.I meet specific health and treatment criteria for a new cancer trial.I agree to use birth control during and after the study for the time required.I do not have an active hepatitis B or C infection.I am HIV-positive with a specific CD4+ cell count and no AIDS-defining illnesses.I do not have any serious ongoing health issues that are not under control.I have recovered from major surgery effects for at least 14 days.My pregnancy-related cancer is confirmed by a specific blood test within the last 28 days.Criterion: For most groups, patients must have a rare cancer confirmed by tests. For the gestational trophoblastic disease group, patients must have the disease confirmed by a specific blood test. Patients with specific gene changes may be included in the study without needing to participate in another test.I have stage I or II thyroid or prostate cancer that is under control.I haven't needed treatment for an autoimmune disease in the last 2 years.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- Group 1: Arm II (nivolumab)
- Group 2: Arm I (nivolumab, ipilimumab)
Frequently Asked Questions
For what medical conditions is Ipilimumab commonly given?
"Ipilimumab can be used to treat conditions such as previous anti-angiogenic therapy, malignant neoplasms, and unresectable melanoma."
Are there any metropolitan hospitals participating in this research project?
"Currently, this trial is being run at 100 different sites. They are situated in locations such as Fremont, Los Angeles and Ontario as well as 100 other places. It would be advantageous to choose the location nearest you to cut down on travel if you decide to participate."
Are there other medical studies that have used Ipilimumab as a treatment?
"Ipilimumab was first trialled in 2009 Texas Children's Hospital. Subsequently, there have been a total of 369 completed trials with 796 currently active trials; many of which are based out of Fremont, California."
What is the FDA's opinion of Ipilimumab?
"While there is some evidence to support the safety of Ipilimumab, it only received a score of 2 because this treatment is still in Phase 2 clinical trials."
Is there still room for more participants in this experiment?
"That is correct. The listing on clinicaltrials.gov indicates that this trial, which was first posted on January 13th 2017, has currently open recruitment and is looking for 818 patients at 100 different sites."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What questions have other patients asked about this trial?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger